Protein S100 Beta as a Predictor of Resuscitation Outcome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Shaare Zedek Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:
NCT00814814
First received: December 24, 2008
Last updated: May 23, 2011
Last verified: May 2011
  Purpose

Management of cardiac arrest is complicated by the lack of a readily available tool identifying individuals who are likely to be successfully resuscitated. S100 beta is a protein that originates in the astroglial cells of the brain, and NSE (Neuron Specific Enolase) is another protein that originates in the neurons themselves. In the laboratory, the concentration of these proteins correlate with evidence of brain damage after head trauma, stroke and exposure to low levels of oxygen. The concentration of these proteins in the blood of human survivors of cardiopulmonary resuscitation in humans is much higher than in patients who were resuscitated but did not survive. However, it is still unclear whether survivors from cardiopulmonary resuscitation have higher levels of these proteins in their blood if they survive with neurological injury secondary to the arrest and resuscitation.

Hypothesis: In humans, the blood concentrations of protein S100 beta and NSE during and after resuscitation can predict who will die despite cardiopulmonary resuscitation and who will survive with neurological injury secondary to the arrest and resuscitation.


Condition
Cardiopulmonary Arrest Outcome

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Protein S100 Beta as a Predictor of the Outcome of Cardiopulmonary Resuscitation

Resource links provided by NLM:


Further study details as provided by Shaare Zedek Medical Center:

Biospecimen Retention:   Samples With DNA

Blood


Estimated Enrollment: 600
Study Start Date: August 2008
Estimated Study Completion Date: January 2012
Groups/Cohorts
Cardiopulmonary arrest

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.

Criteria

Inclusion Criteria:

  • All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.

Exclusion Criteria:

  • Patients with do-not-resuscitate orders or an advance directive to that effect.
  • Patients with intracranial hemorrhage
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00814814

Contacts
Contact: Sharon Einav, MD 972-508-685480 einav_s@szmc.org.il

Locations
Israel
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel, 91031
Contact: Sharon Einav, MD    972-508-685480    einav_s@szmc.org.il   
Contact: Nechama M Kaufman, MN    972-508-685324    nechamak@szmc.org.il   
Hadassah Medical Center Recruiting
Jerusalem, Israel, 91120
Contact: Jeremy D Kark, MD, PhD    972-2-6777113    jeremy1@vms.huji.ac.il   
Sponsors and Collaborators
Shaare Zedek Medical Center
Investigators
Principal Investigator: Sharon Einav, MD Shaare Zedek Medical Center
  More Information

No publications provided by Shaare Zedek Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sharon Einav, MD. Director of Surgical ICU, Shaare Zedek Medical Center
ClinicalTrials.gov Identifier: NCT00814814     History of Changes
Other Study ID Numbers: 14-01-05 A and B (correction)
Study First Received: December 24, 2008
Last Updated: May 23, 2011
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Protein S
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 23, 2014